Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
31.07.2023 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today ...